Allied Market Research


Acute Lung Injury Market

Acute Lung Injury Market Size, Share, Competitive Landscape and Trend Analysis Report by Therapy and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Healthcare

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Acute lung injury is a life-threatening condition caused by severe acute hypoxemic respiratory failure. It is a key source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a substantial impact on public health, with a high incidence across the world and it requires administration of a fast and goal-oriented therapy to suppress further lung damage.

The major factor that drives the acute lung injury market is rise in prevalence of lung-related diseases, increase in geriatric population, growth in awareness about daily health diagnostics, and technological advancements. However, high cost of therapies, and low adoption rate of digital radiography and portable spirometers for diagnosing the condition impede the market growth. Furthermore, advancements in surgical techniques and the perioperative management, and development of new treatment strategies to improve outcomes are expected to provide numerous opportunities for market expansion in the near future.

The global acute lung injury market is segmented based on therapy, end user, and region. Based on therapy, it is categorized into pharmacotherapy, mechanical ventilation, adjunctive procedures, fluid management, and others. Based on end user, it is segmented into hospitals, clinics, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include Altor BioScience Corporation, FirstString Research, Inc., GlaxoSmithKline Plc, Forschung und Entwicklung GmbH, Commence Bio, Inc., CompleGen, Inc., Histocell S.L., Stemedica Cell Technologies, Inc., Windtree Therapeutics, Inc., and S-Evans Biosciences, Inc.

Key Benefits

  • The study provides an in-depth analysis of the global acute lung injury market with current trends and future estimations¬†to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Acute Lung Injury Market Report Highlights

Aspects Details
By Therapy
  • Pharmacotherapy
  • Mechanical Ventilation
  • Adjunctive Procedures
  • Fluid Management
  • Others
By End User
  • Hospitals
  • Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Altor BioScience Corporation, Commence Bio, Inc., GlaxoSmithKline Plc, S Evans Biosciences, Inc, Windtree Therapeutics, Inc., Stemedica Cell Technologies, Inc., CompleGen, Inc., Histocell S.L., FirstString Research, Inc., Forschung und Entwicklung GmbH

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Acute Lung Injury Market

Global Opportunity Analysis and Industry Forecast, 2023-2032